Table 2 Correlation between the expression of IGF-IR or Cbl-b and the clinicopathological factors in primary gastric cancer patients
Factors | All cases | IGF-IR | Cbl-b | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | Negative (%) | Positive (%) | P value | Negative (%) | Positive (%) | P value |
Age a | Â | Â | Â | Â | Â | Â | Â |
 < 59 | 46 | 15 (32.6) | 31 (67.4) | 0.749 | 22 (47.8) | 24 (52.2) | 0.278 |
 ≥ 60 | 54 | 16 (29.6) | 38 (70.4) | 20 (37.0) | 34 (63.0) | ||
Gender | Â | Â | Â | Â | Â | Â | Â |
 Male | 72 | 22 (30.6) | 50 (69.4) | 0.878 | 31 (43.1) | 41 (56.9) | 0.733 |
 Female | 28 | 9 (32.1) | 19 (67.9) | 11 (39.2) | 17 (60.8) | ||
pTNM stage | Â | Â | Â | Â | Â | Â | Â |
 I + II | 46 | 24 (52.2) | 22 (47.8) | <0.001* | 6 (13.0) | 40 (87.0) | <0.001* |
 III + IV | 54 | 7 (13.0) | 47 (87.0) | 36 (66.7) | 18 (33.3) | ||
Lymph node metastasis | Â | Â | Â | Â | Â | Â | Â |
 Absent | 50 | 26 (52.0) | 24 (48.0) | <0.001* | 6 (12.0) | 44 (88.0) | <0.001* |
 Present | 50 | 5 (10.0) | 45 (40.0) | 36 (72.0) | 14 (28.0) | ||
Lauren grade | Â | Â | Â | Â | Â | Â | Â |
 Intestinal | 22 | 8 (36.4) | 14 (63.6) | 0.614 | 7 (31.8) | 15 (68.2) | 0.452 |
 Diffuse | 46 | 12 (26.1) | 34 (73.9) | 22 (47.8) | 24 (52.2) | ||
 mixed | 32 | 11 (34.4) | 21 (65.6) | 13 (40.6) | 19 (59.4) | ||